SOPHARMA AD - Completion of the infusion conversion procedure of “Biopharm Engineering” AD

Spis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Spis załączników:

1. SFA_Biopharm_Merger_complete_espi.pdf Completion of the infusion conversion procedure of “Biopharm Engineering” AD
   

POLISH FINANCIAL SUPERVISION AUTHORITY

UNI - EN REPORT No 94 / 2023

Date of issue: 2023-08-23

Short name of the issuer

SOPHARMA AD

Subject

Completion of the infusion conversion procedure of “Biopharm Engineering” AD

Official market - legal basis

art. 56. 1. 2 of Act on Public Offering.

Unofficial market - legal basis

Contents of the report:

“Sopharma” AD (the Company) notifies that the transformation by merger of "Biopharm Engineering" AD into "Sopharma" AD has been entered in the Commercial Register with number 20230823133229 with which "Biopharm Engineering" AD was deleted without liquidation. The activity of "Biopharm Engineering" AD is completely transferred to "Sopharma" AD, and all the assets of the merging company are transferred to "Sopharma" AD, which becomes its universal legal successor.

Annexes

File Description

SFA_Biopharm_Merger_complete_espi.pdfSFA_Biopharm_Merger_complete_espi.pdf Completion of the infusion conversion procedure of “Biopharm Engineering” AD

SOPHARMA AD

(fullname of the issuer)

SOPHARMA AD Farmaceutyczny (far)

(short name of the issuer) (sector according to clasification of the WSE in Warsow)

1220 Sofia

(post code) (city)

IlienskoShosse 16

(street) (number)

[phone] [phone]

(phone number) (fax)

(e-mail) (web site)

nd

(NIP) (REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Date Name Position / Function Signature

2023-08-23 Ognian Donev Executive director